VENCLEXTA (venetoclax)

TherapyGenentech, AbbVie

VENCLEXTA (venetoclax) from Genentech and AbbVie is a BCL-2 inhibitor used in AML and CLL.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and VENCLEXTA. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where VENCLEXTA is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
B-cell Chronic Lymphocytic Leukemia (CLL) Heme · Leukemia	TP53 Deletion chromosome 17p (17p-)		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for VENCLEXTA.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering VENCLEXTA for eligible patients.

Test

Vysis CLL FISH Probe Kit

Abbott Molecular, Inc.

Method

FISH

Specimen

Whole blood

1 approvalView test profile →

This view is scoped to VENCLEXTA (venetoclax). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.